Interestingly, our study showed that the median ERBB2 copy number in MaBC is significantly lower than in FBC, highlighting additional molecular differences in HER2-positive breast cancer between males and females which may impact sensitivity to anti-HER2 therapy. The gene discussed is ERBB2; the disease is breast cancer.